Impel NeuroPharma scores $67.5 mln Series D

Seattle-based Impel NeuroPharma, a developer of therapies that treat central nervous system disorders with unmet medical needs, has raised $67.5 million in Series D financing. KKR and Norwest Venture Partners led the round with participation from return backers Vivo Capital, 5AM Ventures and venBio Partners.

Source: Press Release

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!